MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP-Reference-Cited by-同舟云学术

MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP

Published:2003-03 Issue:3 Volume:3 Page:259-271
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Deguchi Kenji,Ayton Paul M,Carapeti Melina,Kutok Jeffery L,Snyder Cynthia S,Williams Ifor R,Cross Nicholas C.P,Glass Christopher K,Cleary Michael L,Gilliland D.Gary

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference48 articles.

1. Activation of transcription through histone H4 acetylation by MOF, an acetyltransferase essential for dosage compensation in Drosophila;Akhtar;Mol. Cell,2000

2. The histone H4 acetyltransferase MOF uses a C2HC zinc finger for substrate recognition;Akhtar;EMBO Rep.,2001

3. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins;Ayton;Oncogene,2001

4. A further case of acute myeloid leukaemia with inv(8)(p11q13) and MOZ- TIF2 fusion;Billio;Haematologica,2002

5. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein;Borrow;Nat. Genet.,1996

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer;Advanced Science;2024-07-08

2. A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes;Proceedings of the National Academy of Sciences;2024-06-18

3. Biological and therapeutic insights from animal modeling of fusion-driven pediatric soft tissue sarcomas;Disease Models & Mechanisms;2024-06-01

4. p160 nuclear receptor coactivator family members and their role in rare fusion‑driven neoplasms (Review);Oncology Letters;2024-03-14

5. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment;Biomedicine & Pharmacotherapy;2024-02